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The aim of this study was to investigate the prognostic inﬂuence of microvessel density using the hot spot method in 107
patients diagnosed with transitional cell carcinoma of the bladder. In each case, inﬂammation was found in the invasive
carcinoma, therefore we classiﬁed the degree of inﬂammation as minimal, moderate or intense. Microvessel density was then
reevaluated in each tumour in areas corresponding to these three categories. Median microvessel density irrespective of
degree of inﬂammation was 71. Areas of minimal, moderate and intense inﬂammation were found in 48, 92 and 32 tumours.
Microvessel density increased signiﬁcantly with increasing degree of inﬂammation. Disease-speciﬁc survival was improved if
areas of intense inﬂammation were present in the carcinoma (P=0.004). High microvessel density, irrespective of the degree
of inﬂammation, was associated with a signiﬁcantly better disease-speciﬁc survival (P=0.01). Multivariate analysis using death of
disease as endpoint demonstrated an independent prognostic value of N-classiﬁcation (N0, hazard ratio (HR)=1 vs N1,
HR=2.89 (range, 1.52–5.52) vs N2, HR=3.61 (range, 1.84–7.08)), and intense inﬂammation, HR=0.48 (range, 0.24–0.96).
Malignancy grade, T classiﬁcation and microvessel density were not independent signiﬁcant markers of poor outcome. In
conclusion, inﬂammation was signiﬁcantly correlated to microvessel density, and areas of intense inﬂammation were an
independent marker of good prognosis.
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Angiogenesis, the development of new vessels from pre-existing
vessels, is involved in the growth, maintenance and metastasis of
most solid tumours (Zetter, 1988). Several groups have investigated
the prognostic signiﬁcance of estimates of tumour angiogenesis in
bladder carcinoma. Although these studies (Dickinson et al, 1994;
Bochner et al, 1995; Jaeger et al, 1995; Philp et al, 1996; Chaudhary
et al, 1999; Inoue et al, 2000) used slightly different methods, they
support a theory that a highly vascular bladder carcinoma behaves
more aggressively than a carcinoma with a low vascular density.
The development of new vessels is inﬂuenced by pro-angiogenic
factors, vascular endothelial growth factor (VEGF) being one of
the most potent stimulators of angiogenesis (Ferrara, 1999). Carci-
noma cells, plasma cells, and T lymphocytes have been shown to
synthesise VEGF (Freeman et al, 1995; Ito et al, 1995), implying
that inﬂammation can inﬂuence angiogenesis, but no agreed
guidance exists on how to deal with inﬂammation when estimating
angiogenesis. To our knowledge no studies on estimates of angio-
genesis in relation to inﬂammation have been published.
Inﬂammation is a frequent ﬁnding in bladder carcinoma and
may be of prognostic signiﬁcance. In a study on 428 cases of
primary superﬁcial bladder carcinoma, patients with an inﬂamma-
tory reaction in their tumour experienced signiﬁcantly fewer
recurrences and cancer-related deaths compared to those with
tumours without inﬂammation (Flamm, 1992). Another study on
56 patients with invasive bladder carcinoma reported a signiﬁcantly
better 1-year survival when lymphocytes, plasma cells and/or
lymph follicles were present in the tumours (Mihatsch et al,
1979). These ﬁndings suggest a protective role of inﬂammation.
The possible positive inﬂuence of toxins on cancer has been known
for many years. Indeed, Coley’s observations in 1893 initiated
studies on the possible anti-cancer effects of Coley’s toxin (Coley,
1893). The cure of a patient with recurrent lymphosarcoma after
two erysipelas infections prompted Coley to use ﬁltered bacterial
extracts (Coley’s toxin) for adjuvant carcinoma therapy. More
recently, use has been made of the anti-tumour effects of inﬂam-
mation by inducing a local immune response to BCG (bacillus
of Calmette and Guerin) instillations into the bladder in patients
with urothelial tumours. The precise mechanisms involved in this
process are still to be clariﬁed (Alexandroff et al, 1999; Bohle,
2000). In 1986, Jass classiﬁed inﬂammation in the invasive part
of adenocarcinomas of the rectum as pronounced, moderate, and
little or none (Jass, 1986). He found that high degree of inﬂamma-
tion in close association with the invasive carcinoma was an
independent parameter of good prognosis.
In the present study, we investigated the prognostic impact of
estimates of angiogenesis in invasive bladder carcinoma. Our initial
studies showed an unexpectedly high frequency of inﬂammation
associated with the invasive tumour component. This prompted
us to analyse angiogenesis in relation to the degree of inﬂamma-
tion, and to correlate these estimates with other known
prognostic factors, disease-speciﬁc and overall survival.
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Patients
Based on cystoscopy and biopsy 107 consecutive patients diagnosed
with transitional cell carcinoma of the bladder were considered
candidates for radical cystectomy at the University Hospital of
Aarhus, Denmark, between January 1, 1992 and December 31,
1998. The study was carried out with ethical committee approval.
Tumour, Nodal, Metastasis (TNM) classiﬁcations were based on
the guidelines of the International Union against Cancer (UICC),
1992, and morphological classiﬁcation and grading of the tumours
were performed according to Bergkvist et al (1965) by one
uropathologist. Formalin-ﬁxed and parafﬁn-embedded surgical
specimens of invasive tumour tissue coming from transurethral
resection of the bladder (TUR-B) were used in the present study.
The characteristics of the patients are listed in Table 1 with regard
to sex, age, clinical T classiﬁcation (based on TUR-B and bimanual
palpation), pathological N classiﬁcation (based on ﬁndings during
precystectomy staging operation or cystectomy), and histopatholo-
gical grade. In six cases no lymph nodes were identiﬁed in the
cystectomy specimen. Following evaluation by chest X-ray, excre-
tory urogram, bone scintigraphy and either ultrasound, CT, or
MR, all tumours were classiﬁed as M0. Eight cases (50%) with
T1 had CIS in the TUR-B specimen.
Eight patients (7%) had previous BCG instillations into the
bladder. Eighty-seven patients (81%), mainly with muscle-invasive
tumours, underwent a pre-cystectomy staging operation with uni-
or bilateral pelvic lymphadenectomy. Based on this, 40 patients
(37%) (three N0,1 9N 1,1 8N 2) were treated with radiotherapy
(60 Gy) and/or chemotherapy, and 67 patients (63%) underwent
radical cystectomy. All time estimates were made using the date
of TUR-B just before staging and/or cystectomy as the initial value,
and the patients were followed until death or August 1, 2001. At
analysis, 60 patients (56%) had died from bladder carcinoma,
and eight patients (7%) had died with no evidence of disease.
Median follow-up was 33 months (range, 4–85 months). Median
time to death for the 60 patients who died from bladder carcinoma
was 18 months (range, 4–67 months). No patients were lost to
follow-up or omitted from the analyses for other reasons.
Microvessel staining
In 81 cases (76%) one parafﬁn block from the TUR-B contained
tumour, whereas two, three, and four tumour containing parafﬁn
blocks were available in 18 (17%), six (5%), and two cases (2%),
respectively. When more than one block was available we used
the same parafﬁn block as had been used previously by the pathol-
ogist for histopathological diagnosis. Each case was represented by
a single section. Sections were mounted on silanised glass slides
and stored in the dark at 58C before staining within 1 week. After
removal of parafﬁn and rehydration, tissue sections underwent
antigen retrieval by microwave heating in 10 mM Tris and
0.5 mM EGTA buffer (Titriplex
1 VI, Merck Eurolab, Copenhagen,
Denmark) (pH 9.0) twice for 5 min. Endogeneous peroxidase was
blocked by incubation in 5% H2O2 in distilled water for 20 min at
room temperature, before overnight incubation at 48C with an
anti-CD34 monoclonal antibody (clone QB-END 10, Immunotech,
Marseille, France) diluted 1:200 in Antibody Diluent (S809, Dako,
Glostrup, Denmark) to label endothelial cells. Bound primary anti-
body was detected by the application of Envision+
TM (Dako
Envision+
TM, Peroxidase, Mouse, K4001). Intervening washes were
performed in Tris/PBS for 5 min. The antigen-antibody complex
was visualised using the chromogen 3-amino-9-ethylcarbazole (a-
5754, Sigma-Aldrich, Copenhagen, Denmark), counterstained with
Mayer’s haematoxylin and mounted in DAKO Glycergel (code No.
C 0563).
Microvessel quantiﬁcation
Tumours were scanned at 640–100 magniﬁcation for areas in the
invasive carcinomas demonstrating the highest microvascular
density (MVDmax) and estimates of angiogenesis were made using
a1 0 610 grid in the ocular projected onto this area using a slight
modiﬁcation of the method ﬁrst described by Weidner et al (1991)
and used by us previously (Offersen et al, 2001). The counts were
done at 6200 magniﬁcation, area 0.25 mm
2. All sections showed
adequate staining. All the counts were done without knowledge
of patient outcome by a single observer (BVO).
Evaluation of inﬂammation
During initial measurements of MVDmax, inﬂammation within
the invasive component of the carcinomas was noted to be far
more intense than we had encountered previously when estimat-
ing angiogenesis in carcinomas of the prostate, lung and breast.
Therefore, we established a semiquantitative scale to assess the
degree of inﬂammation, which to our knowledge has not been
described in bladder carcinoma. Inﬂammation was scored as:
minimal inﬂammation (less than ﬁve lymphocytes within the
10610 grid at 6200, area 0.25 mm
2); moderate inﬂammation
(mononuclear inﬂammatory cells scattered throughout the tissue
but background stromal connective tissue still clearly visible);
intense inﬂammation (mononuclear inﬂammatory cells densely
inﬁltrating the tissues lying side-by-side). The degree of inﬂam-
mation in the individual tumours was assessed throughout the
invasive carcinoma component. Although lymphoid follicles with
germinal centres were encountered these were not separately
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Table 1 The association between clinicopathological variables and
degree of inﬂammation
Degree of inﬂammation
All (%) Intense Moderate
All 107 (100) 32 (100) 75 (100)
T classiﬁcation
a
T1 16 (15) 7 (22) 9 (12)
T2 39 (36) 13 (41) 26 (35)
T3a 31 (29) 7 (22) 24 (32)
T3b 12 (11) 2 (6) 10 (13)
T4a 9 (8) 3 (9) 6 (8)
N classiﬁcation
b
N0 61 (57) 22 (69) 39 (52)
N1 21 (20) 6 (19) 15 (20)
N2 19 (18) 2 (6) 17 (23)
Nx
c 6 (6) 2 (6) 4 (5)
Malignancy grade
e
II
d 1 1 (3) 0 (0)
III 89 29 (91) 60 (80)
IV 17 2 (6) 15 (20)
Gender
Male 91 (85) 26 (81) 65 (87)
Female 16 (15) 6 (19) 10 (13)
Age
464 years 51 (48) 17 (53) 34 (45)
464 years 56 (52) 15 (47) 41 (55)
aClinical T classiﬁcation based on TUR-B and bimanual palpation.
bPathological N clas-
siﬁcation based on precystectomy staging operation or cystectomy.
cIn six cases no
lymph nodes were identiﬁed in the cystectomy specimen (excluded from statistical
analysis).
dexcluded from statistical analysis in this table.
eP=0.04. Percentages are
rounded numbers.
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MVD in areas of minimal, moderate or intense inﬂammation
were designated MVD1, MVD2, and MVD3, respectively. The
reproducibility of identifying the different degrees of inﬂamma-
tion was tested in 20 randomly chosen tumours. Estimates of
MVD in areas of the three different degrees of inﬂammation were
done on three separate occasions. Sections from 10 randomly
chosen tumours were blindly recounted to test reproducibility
of the MVD scores.
VEGF immunohistochemical assay
Parallel sections to the anti-CD34 stained slides were processed as
described above, except for being microwaved in buffer for
365 min. They were then incubated with anti-VEGF (sc152, rabbit
polyclonal IgG, 200 mgm l
71; Santa Cruz Biotechnology, CA, USA)
diluted 1:2000 in Antibody Diluent (Dako) overnight at 48C. This
antibody reacts with the 121, 165, and 189 amino acid splice
variants of VEGF of human origin. Bound primary antibody was
detected by Dako Envision+
TM (peroxidase, rabbit, code no.
K4003) for 30 min, followed by 7 min incubation in Vector
1
NovaRED
TM (Substrate kit for peroxidase, SK-4800, Vector
Laboratories, Burlingame, CA, USA). Slides were counterstained
with Mayer’s haematoxylin, and mounted in a non-aqueous media
(DPX, BDH Laboratory Supplies, Poole, UK). Intervening washes
were performed in Tris/PBS (pH 7.6) with added 0.25% Triton
X-100. The positive control was a section of prostate carcinoma
previously shown to have a high VEGF content by immunohisto-
chemistry. VEGF staining was considered positive if appropriate
red staining was seen in the cell cytoplasm.
Statistical methods
The reproducibility of the MVD method was tested in accordance
to the guidelines suggested by Bland and Altman (1986), thus scat-
ter plots and difference plots were made to graphically show the
reproducibility. MVD1 and MVD2 were compared with a
Mann–Whitney U-test, because although both counts were
normally distributed, a F-test showed signiﬁcantly higher variances
in the inﬂammatory group (MVD2). MVD2 and MVD3 were
compared with a t-test. A w
2 test was used when looking for a
correlation between the different vascular estimates dichotomised
by their median values and other known clinicopathological para-
meters. Survival functions were performed according to the
Kaplan–Meier method, differences in survival curves being calcu-
lated according to the log-rank test. A multivariate Cox
proportional hazards regression analysis was used to investigate
the prognostic value of the clinicopathological parameters with
respect to death of disease or overall death applying a backward
LR test. Univariate and Cox multivariate analyses were done using
the SPSS 10.0 program package. All P-values were based on two-
sided testing and the level of statistical signiﬁcance was 5%.
RESULTS
MVDmax
Median MVDmax was 71 (range, 21–249). MVDmax dichotomised
by the median value was independent of the clinicopathological
factors mentioned in Table 1, i.e. T and N classiﬁcation, malig-
nancy grade, gender and age (data not shown). Furthermore,
MVDmax dichotomised by the median value is shown in Figure 1
and illustrates a signiﬁcantly better disease-speciﬁc survival of the
patients whose tumours had a vascular score 571 (P=0.01).
Reproducibility was acceptable, as all the recounts were highly
correlated in the scatter plots and were situated between the lines
of +2 s.d. in Figure 2.
Inﬂammation
All of the 107 carcinomas had areas of inﬂammation in their inva-
sive component, but the degree varied, and indeed, most of the
tumours had at least two different degrees of inﬂammation in
different areas of the invasive carcinoma. Table 2 demonstrates
the reproducibility of identifying the different degrees of inﬂamma-
tion in the carcinomas. In 13 (65%) tumours the inﬂammatory
scores were identical. Nine of the tumours had areas of intense
inﬂammation identiﬁed either in the ﬁrst or the second round,
and in six (2 out of 3) of these tumours the ﬁrst and second scores
were similar.
Forty-eight of the tumours (45%) had areas in the invasive
carcinoma with minimal associated inﬂammation (Figure 3A).
However, in each of these 48 tumours, areas of moderate inﬂam-
mation were also present in other parts of the carcinoma. In
another 44 tumours, areas of moderate inﬂammation were present
in the carcinoma, and these tumours had no areas of minimal
inﬂammation. Thus, in a total of 92 tumours (86%) (Figure 3B)
areas of moderate inﬂammation were present. Areas of intense
inﬂammation were encountered in 32 cases (30%) (Figure 3C),
15 being intensely inﬂamed throughout the carcinoma, nine also
showing areas with moderate inﬂammation, and eight showing
areas with all three degrees of inﬂammation. Table 1 shows that
the degrees of inﬂammation were independent of other known
clinico-pathological variables, except malignancy grade. The prog-
nostic value of inﬂammation was then investigated, and the
tumours were separated in those with areas of intense inﬂamma-
tion as compared to those with areas of moderate inﬂammation
(Figure 4). The survival plot showed a signiﬁcantly better
disease-speciﬁc survival if areas of intense inﬂammation were
present in the carcinoma (P=0.004), with the estimated 4 year
disease-speciﬁc actuarial survival rate being 65% if intense inﬂam-
mation was present in invasive bladder carcinoma compared to
34% when it was not present.
MVD and VEGF in areas of inﬂammation
The median value of MVD1 was 32 (range, 7–100), median
MVD2 was 63 (range, 21–217), and median MVD3 was 105
(range, 32–249) (Figure 5). The vascular scores increased signiﬁ-
cantly with increasing degree of inﬂammation (P50.0001).
Neither of the vascular scores could separate the clinicopathological
variables shown in Table 1 indicating that the vascular scores were
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Figure 1 Disease-speciﬁc survival stratiﬁed by MVDmax evaluated
irrespective of degree of inﬂammation dichotomised on the median value
(MVDmax high 571).
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British Journal of Cancer (2002) 87(12), 1422–1430 ã 2002 Cancer Research UKindependent parameters. VEGF staining showed in all but a few
cases that the staining intensity was very strong in both the carci-
noma cells and the non-neoplastic cells, Figure 3D.
Multivariate analysis
A Cox multivariate analysis was performed using death from blad-
der carcinoma as the endpoint. As N status was uncertain in six
cases, we omitted these patients from the multivariate analysis,
which therefore was performed in 101 patients with all variables
available. Table 3 shows all the variables included in the model.
Notice, that in this model, degree of inﬂammation was an indepen-
dent variable, whereas MVDmax was not independent. However, if
degree of inﬂammation was omitted from the model, MVDmax
evaluated as a continuous parameter was almost an independent
prognostic parameter (HR=0.992, 95% CI 0.984–1.001, P=0.08).
Using overall death as endpoint in the multivariate analysis showed
the close association between degree of inﬂammation and MVDmax,
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Figure 2 Intraobserver data for the reproducibility of the MVD counts. Left column shows the bivariate scatter plots. In each plot the correlation coefﬁ-
cient r
2, slope with corresponding 95% conﬁdence interval, and intercept with the Y-axis with corresponding 95% conﬁdence interval are listed. Right column
shows the difference plots; solid line:mean intraobserver difference and dotted line:95% limits of agreement (+2 s.d.).
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Figure 3 (A–C) Shows examples of minimal, moderate and intense inﬂammation, respectively. CD34-positive vessels are highlighted with red and
counterstained with haematoxylin. Notice in C carcinoma cells lying in close relation to the inﬂammatory cells. (D) Shows VEGF staining of an adjacent
section to B. Notice the intense staining of inﬂammatory cells in the stroma and of the carcinoma cells. Bar is 100 mm.
Table 2 The reproducibility between ﬁrst and second identiﬁcation of degree of inﬂammation in 20 randomly chosen tumours. Tumours with similar
results are bold
First estimate of degree of inﬂammation Second estimate of degree of inﬂammation
Tumour Low Moderate Intense Low Moderate Intense
1 XX XX
2X X X
3X X X X X
4 XX XX
5X X X
6X X X
7 XX XX
8 XX XX
9 XX
10 X X X X
11 XX XX
12 XX XX
13 XX
14 XX XX
15 XX
16 XX
17 XX XX
18 XX XX
19 X X
20 XX XX
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British Journal of Cancer (2002) 87(12), 1422–1430 ã 2002 Cancer Research UKsince MVDmax now was an independent variable, while degree of
inﬂammation lost importance (Table 4).
DISCUSSION
We investigated the potential prognostic value of microvascular
density in invasive bladder carcinoma. During our initial attempts
to count MVDmax, inﬂammation was identiﬁed as a complicating
factor. Therefore, we established a semiquantitative score of inﬂam-
mation in relation to which vascular densities could be evaluated.
Our analysis showed signiﬁcantly increased vascular density with
increasing degree of inﬂammation, and identiﬁed areas of intense
inﬂammation in the invasive carcinoma as a new independent indi-
cator of good prognosis. Estimates of angiogenesis were found to
be associated with inﬂammation, since the vascular densities
increased with increasing degree of inﬂammation. Both carcinoma
and non-neoplastic cells were identiﬁed as contributors of VEGF in
the tissues implying that both cell types may stimulate angiogenic
processes. The predominant inﬂammatory cell types found in the
tumours in the present study were lymphocytes and plasma cells
reﬂecting a chronic inﬂammatory response to the tumour, but
polymorphonuclear cells (PMN) were also encountered reﬂecting
signs of acute inﬂammation. Recently it has been demonstrated
that activated PMNs can release VEGF from intracellular stores
and thereby stimulate angiogenesis (McCourt et al, 1999).
The presence of inﬂammation was evaluated in one histological
section from the same parafﬁn block which had been used for
diagnostical histopathological evaluation in each patient. This was
selected by the pathologist as the one containing most representa-
tive carcinoma. Others have investigated the intratumour
variability of MVD estimates in breast carcinomas, and found that
the largest contributor to total variation was the intertumour varia-
tion (de Jong et al, 1995). The variation among sections from the
same tumour block was evaluated and compared to the variation
among different tumour blocks from the same tumour and
between tumours, and de Jong et al (1995) reported ‘that variation
between blocks contributed most to the total variation (60%),
followed by variation within blocks (34%) and sections (6%)’.
Furthermore, they compared MVD evaluated by the hot spot
method with MVD evaluated with a systematic random technique,
and concluded: ‘When comparing the systematic counts with the
hot spot counts, the relatively low variation within blocks speaks
in favour of the hot spot method, because this implies that from
available blocks, only one section has to be scanned to ﬁnd the
hot spot’. On the other hand, considerable variation in MVD esti-
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Figure 4 Disease-speciﬁc survival stratiﬁed by tumours with areas of
intense and moderate inﬂammation in bladder carcinoma.
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Figure 5 Distribution of MVD evaluated in areas of different degrees of
inﬂammation. Inﬂammation group 1 was ‘minimal inﬂammation’, group 2
was ‘moderate inﬂammation’, and group 3 was ‘intense inﬂammation’.
Table 3 Cox multivariate analyses of the prognostic value of clinical
characteristics using death from bladder carcinoma as endpoint in 101
patients with all variables available. Hazard ratio (HR) and 95% confidence
intervals (95% CI) are listed for all variables included in the model
Variable P HR 95% CI
N0 1
N1 0.001 2.89 (1.52–5.52)
N2 50.0001 3.61 (1.84–7.08)
T1 1
T2 0.91 0.94 (0.33–2.66)
4T2 0.06 2.44 (0.95–6.26)
Moderate inﬂammation 1
Intense inﬂammation 0.04 0.48 (0.24–0.96)
Malignancy grade II+III 1
Malignancy grade IV 0.55 0.79 (0.36–1.72)
MVDmax, continuous 0.40 0.996 (0.987–1.005)
Table 4 Cox multivariate analyses of the prognostic value of clinical
characteristics using overall death as endpoint in 101 patients with all
variables available. Hazard ratio (HR) and 95% conﬁdence intervals (95%
CI) are listed for all variables included in the model
Variable P HR 95% CI
N0 1
N1 0.02 2.08 (1.13–3.81)
N2 0.001 3.08 (1.62–5.85)
T1 1
T2 0.86 0.92 (0.38–2.24)
4T2 0.11 1.93 (0.86–4.35)
Moderate inﬂammation 1
Intense inﬂammation 0.37 0.72 (0.36–1.47)
Malignancy grade II+III 1
Malignancy grade IV 0.60 0.83 (0.41–1.68)
MVDmax, continuous 0.03 0.991 (0.983–0.999)
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another study (Ahlgren et al, 2002). In the present study we have
not investigated the variability of degree of inﬂammation in single
parafﬁn blocks, nor among parafﬁn blocks from the same tumour.
Five other studies estimating angiogenesis in bladder carcinoma
based on counting in hot spots have been published (Table 5).
Four of these reported high vascular density to be associated with
poor prognosis (Dickinson et al, 1994; Bochner et al, 1995;
Chaudhary et al, 1999; Inoue et al, 2000) whereas one showed high
vascular density to be associated with classical prognostic factors at
diagnosis (Jaeger et al, 1995). None of the studies mentioned the
possible inﬂuence of inﬂammation in the carcinomas and how to
deal with it when identifying the area of highest vascular density.
In contrast to the present study, which investigated tissue removed
during a TUR-B before cystectomy, Bochner et al (1995) investi-
gated tissue from cystectomies of presumably consecutive
patients. In our experience the latter tissue is typically more
inﬂamed than tissue from a TUR-B. In the study by Dickinson
et al (1994), tissue from TUR-B on 45 patients was used. Although
inﬂammation was not mentioned, we judge from the colour illus-
tration in the paper that estimates of angiogenesis were performed
also in invasive tumour areas with signs of moderate inﬂammation.
Their study investigated the prognostic value of estimates of angio-
genesis in bladder carcinoma, however, they did not state the
prognostic value of their Chalkley counts dichotomised on the
median value, but used an ‘optimal cutpoint’. The study by Jaeger
et al (1995) on 41 patients correlated estimates of tumour angio-
genesis with lymph node metastases; no follow-up was reported.
The most recent study identiﬁed high MVD as an independent
parameter of poor prognosis in cystectomy specimens but not in
TUR-B specimens. However, this was based on 55 patients only
(Inoue et al, 2000). None of the studies mentioned in Table 5 used
the same counting area as we did, therefore the cut-off points
introduced in the studies are not directly comparable with the
present study. Two of the studies in Table 5 used the Chalkley grid,
which provides a kind of area estimate. In the current study we
have also used the Chalkley grid as previously described (Offersen
et al, 2001), and the Chalkley scores revealed the same results and
led to the same conclusions as the MVD scores have done (data
not shown). However, we preferred to report only the MVD
method in this type of carcinoma, because the Chalkley scores,
being a kind of area estimate, could in theory be inﬂuenced by
vasodilation caused by the inﬂammatory cells.
VEGF is one of the key regulators of the angiogenic processes,
therefore, we decided to evaluate the staining of this factor. The
antibody used reacts with the 121, 165, and 189 amino acid splice
variants; VEGF121 is freely diffusible, VEGF165 is bound both on
cell surfaces and in the extracellular matrix (ECM) as well as being
secreted, and VEGF189 is almost completely sequestered in the
ECM (Ferrara, 1999). The receptors for VEGF are of the tyrosine
kinase family (VEGFR-1, VEGFR-2 and VEGFR-3) and are largely
restricted to vascular endothelial cells (Ferrara, 1999; Yancopoulos
et al, 2000). However, evidence exists that VEGFR-1 is also transi-
ently located in a subgroup of highly differentiated prostate
carcinoma cells (Hahn et al, 2000) and on macrophages (Sawano
et al, 2001). To our knowledge no reports have demonstrated the
localisation of VEGF receptors on inﬂammatory cells, therefore,
the intense staining of the inﬂammatory cells in this study repre-
sents genuine VEGF production in these cells. Indeed, by
demonstrating VEGF mRNA in T cells inﬁltrating human bladder
and prostate carcinoma by in situ hybridisation, Freeman et al
(1995) suggested that lymphocytes play an active role in the regu-
lation of angiogenesis, not associated with other immune reactions
but driven by VEGF. Hypoxia is the primary stimulator of VEGF
synthesis (Ferrara, 1999), but it has lately been demonstrated that
release of VEGF from neutrophils may occur independently of
hypoxia (Koehne et al, 2000). Taken together, this suggests that
the ‘host factor’ has to be taken into account when evaluating blad-
der carcinomas. For example, in a study by O’Brien et al (1995)
different angiogenic pathways are suggested based on measure-
ments of VEGF using a RNase protection analysis. They found
the VEGF content in superﬁcial tumours four-fold higher than in
the invasive tumours and 10-fold higher than in normal bladder
tissue, but these measurements may be inﬂuenced by VEGF from
host cells. Recently, another group has tried to measure the relative
contribution to VEGF production of host vs tumour cells (Tsuzuki
et al, 2000). VEGF
7/7 and wild-type embryonic stem cells were
implanted in severe combined immunodeﬁcient mice, and VEGF
ELISAs showed that in the VEGF
7/7 embryonic stem cell-derived
tumours the content of VEGF was about half that in the wild-type
derived tumours, the host cells contributing the other half.
To our knowledge, inﬂammation has not been described as an
independent prognostic factor in invasive bladder carcinoma,
although pronounced lymphocytic inﬁltration at the advancing
tumour front was identiﬁed by Jass (1986) as an independent prog-
nostic parameter in rectal adenocarcinomas. The survival advantage
we describe may reﬂect a host versus tumour response, as also
suggested by Jass, but this will require further analysis for conﬁr-
mation.
Most of the tumours included in the present study were muscle
invasive, and it was shown that malignancy grade was not a signiﬁ-
cant independent variable. Previously, malignancy grade has been
established as an independent prognostic variable in non-invasive
bladder tumours, however, as stated in a WHO consensus classiﬁ-
cation of urothelial neoplasms ‘invasive tumours should be graded
as low or high’ (Epstein et al, 1998), since there is no difference in
the outcome of patients diagnosed with muscle-invasive tumours
of either grade III and IV. For example, Jimenez et al (2000) inves-
tigated the prognostic potential of malignancy grading in 93
muscle-invasive bladder tumours and found no difference in
outcome between grade III and IV, and similar results were seen
in the study by Bassi et al (1999) who investigated 369 bladder
tumours, where 258 (70%) were muscle-invasive: malignancy grade
was not an independent variable. In a study from Bostwick’s group
(co-author on the WHO consensus classiﬁcation) malignancy
grade III and IV a.m. Bergkvist are classiﬁed together as ‘high
grade’ (Cheng et al, 2000). Thus, it is not surprising that we found
no difference in the prognosis between patients diagnosed with
grade III and IV muscle-invasive tumours.
In the current study 67 patients (63%) underwent radical
cystectomy and 40 patients (37%) received radio- and/or
chemotherapy. As systemic therapy was given to patients with
advanced disease, the outcome of these patients was strongly inﬂu-
enced primarily by T and N status. There was no difference in the
outcome of the patients in multivariate analysis with regard to
cystectomy or chemo- or radiation therapy. Only eight cases in
our study had a history of BCG instillation of the bladder, two
of them had tumours with intense inﬂammation somewhere in
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Table 5 Overview of the studies investigating estimates of angiogenesis
using methods based on hot spots in bladder carcinoma. All these studies
have found high estimates of angiogenesis associated with poor prognosis,
except the study from Jaeger’s group, where high MVD was associated with
presence of lymph node metastases
No Method and
Author points T-class Antibody magniﬁcation
Dickinson et al (1994) 45 T2–3 CD31 Chalkley 6100
Bochner et al (1995) 164 T1–4 CD34 MVD 6200
Jaeger et al (1995) 41 T2–4 VWF MVD 6200
Chaudhary et al (1999) 88 Ta–4 CD31 Chalkley 6400
Inoue et al (2000) 55 T2–4 CD34 MVD 6100
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are seen quite soon, and then tend to disappear. However, germ-
inal centres were not considered in this study.
Our ﬁndings reveal a signiﬁcant association between increasing
degrees of inﬂammation and rising estimates of angiogenesis. High
degree of inﬂammation were identiﬁed as an independent prognos-
tic factor using death of disease as the endpoint, the relative risk
being 0.48 when areas of intense inﬂammation were present. When
evaluating MVD irrespective of inﬂammation a signiﬁcantly better
overall and disease-speciﬁc survival was found for patients with
tumours of high vascular density. MVDmax and degree of inﬂam-
mation was closely associated, and using overall death as the
endpoint identiﬁed MVDmax as an independent parameter, while
inﬂammation lost importance. Using VEGF stained sections we
demonstrated both carcinoma and host inﬂammatory cells as
contributors of VEGF to the tissues. The fact that inﬂammation
in bladder carcinoma indicates a good prognosis may reﬂect the
ability of the patient to mount an immune response. As seen in
Figure 3, the areas of intense inﬂammation show the immune cells
in direct contact with the carcinoma cells. Our ﬁndings also point
towards angiogenesis being associated with inﬂammation in blad-
der carcinoma and being regulated by a delicate balance between
factors from both the tumour and the patient. Previous research
on angiogenesis has been based solely on the carcinoma cells as
contributors of different angiogenic factors (Hanahan and Folk-
man, 1996), however, our data show that reactive cells take an
active part in the stimulation of angiogenesis and, therefore, need
to be taken into account in the design of future angiogenic
strategies.
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